People: Taro Pharmaceutical Industries Ltd. (TAROF.PK)
TAROF.PK on USA Pink Sheets
10.25USD
9 Feb 2010
10.25USD
9 Feb 2010
Price Change (% chg)
$-0.05 (-0.49%)
$-0.05 (-0.49%)
Prev Close
$10.25
$10.25
Open
--
--
Day's High
$10.35
$10.35
Day's Low
$10.15
$10.15
Volume
4,700
4,700
Avg. Vol
5,041
5,041
52-wk High
$10.62
$10.62
52-wk Low
$7.50
$7.50
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Levitt, Barrie | 71 | 1991 | Chairman of the Board |
| Kolker, Ron | 52 | 2008 | Chief Financial Officer, Senior Vice President |
| Yacobi, Avraham | 60 | 1998 | Senior Vice President - Research and Development |
| Bayer, Hannah | 56 | 2006 | Group Vice President - Finance, Chief Accounting Officer |
| Kaplan, Roman | 60 | Vice President - Technical Operations, Pharmaceuticals | |
| Dichter, Yohanan | 59 | 2006 | Vice President - Pharmacist in Charge and Senior Quality Manager |
| Bacalu, Mariana | 56 | Vice President - Quality Affairs | |
| Tal, Tzvi | 56 | Vice President - Information Technology, Israel | |
| Zajicek, Ram | 43 | 2006 | Group Vice President, Haifa Site Manager |
| Reingold, Hagai | 41 | Vice President - API Division, Israel | |
| Rothman, Inbal | 35 | Vice President - Human Resources and Community Affairs, Israel | |
| Shamir, Noam | 47 | Vice President - Supply Chain & Industrial Engineering | |
| Roof, Rebecca | 51 | 2006 | Interim Chief Administrative and Restructuring Officer |
| Levitt, Tal | 37 | 2006 | Secretary, Director |
| Rafalowicz, Zahava | 59 | Group Vice President - Sales and Marketing, Deputy General Manager, Israel | |
| Rubinstein, Samuel | 67 | Senior Vice President, General Manager | |
| Moros, Daniel | 58 | Vice Chairman of the Board | |
| Douglas, Heather | 52 | 1998 | Director |
| Johnston, Eric | 62 | 1984 | Director |
| Keren, Gad | 54 | 2001 | Director |
| Strober, Myron | 76 | 2002 | Director |
| Friedman, Micha | 65 | 2002 | Director |
| Hod, Ben | 52 | 2006 | Director |
| Fainaro, Haim | 63 | 2003 | Director |
Biographies
| Name | Description |
|---|---|
| Levitt, Barrie | Barrie Levitt, M.D. became Chairman of the board of directors of Taro Pharmaceutical Industries Ltd. in 1991. Dr. Levitt has been a director since 1963. Dr. Levitt, a pharmacologist (basic as well as clinical), has been involved in pharmacologic research and clinical cardiology since 1963. From 1974 to 1977, he was Professor of Medicine and Pharmacology and Director of Cardiology and Clinical Pharmacology at New York Medical College. From 1977 to 1985, he was Clinical Professor of Medicine and Visiting Professor of Pharmacology at the Albert Einstein College of Medicine in New York. From 1982 to 2000, he was Chairman of the Committee on Clinical Investigations at that institution. Dr. Levitt is a Fellow of the American College of Cardiology and of the American College of Clinical Pharmacology. He is a member of the American Society for Pharmacology and Experimental Therapeutics. In addition, Dr. Levitt served as a consultant to the FDA from 1971 through March 1991, when he resigned in order to increase his involvement in the company. |
| Kolker, Ron | Ron Kolker, C.P.A. is Chief Financial Officer, Senior Vice President of Taro Pharmaceutical Industries Ltd. and its U.S. subsidiary, Taro Pharmaceuticals U.S.A., Inc. Mr. Kolker joined Taro in 1994 and has held a number of roles in finance at the Company with increasing responsibility. He most recently held the position of Group Vice President, Corporate Controller in both the Company and Taro USA, and also served as the Company's Interim Chief Financial Officer for part of 2007. Mr. Kolker is a Certified Public Accountant and holds an MBA in Finance and Accounting. |
| Yacobi, Avraham | Avraham Yacobi, Ph.D. joined Taro Pharmaceutical Industries in 1994 as President of the Institute and was appointed Senior Vice President, Research and Development in 1998. Dr. Yacobi directs the pharmaceutical, scientific and regulatory initiatives. Prior to joining the company, he was the Director of Pharmacodynamics Research for the Medical Research Division of American Cyanamid Company from 1982 to 1994. From 1976 to 1982, Dr. Yacobi served as Section Head of Clinical Pharmacology and Drug Metabolism of American Critical Care. He has extensive experience in drug development, with over 120 publications in the field. |
| Bayer, Hannah | Hannah Bayer, C.P.A. joined Taro Pharmaceutical Industries in 2001 as Vice President and Chief Accounting Officer. In 2006, she was promoted to Group Vice President, Finance and Chief Accounting Officer. Ms. Bayer is a Certified Public Accountant in Israel. From 1999 to 2000, she served as Chief Financial Officer of Omrix Biopharmaceuticals, Ltd. From 1990 to 1999, Ms. Bayer held several financial positions in Teva Pharmaceutical Industries Ltd. |
| Kaplan, Roman | Roman Kaplan, Ph.D. joined Taro Pharmaceutical Industries in 1991 and currently serves as Vice President, Technical Operations, Pharmaceuticals. He is responsible for process and product formulation improvements. Dr. Kaplan served from 1982 to 1987 as project manager of the biochemical laboratory of Abic Chemical and Pharmaceutical Industries and from 1987 to 1991 as head of its solid dosage forms development group. |
| Dichter, Yohanan | Yohanan Dichter joined Taro Pharmaceutical Industries in 1986 in the research department and since 1988 has served as the Vice President, Pharmacist in Charge of the Haifa Bay pharmaceutical manufacturing plant. In 2006, he was also named as Senior Quality Manager. He is responsible for the review and release of all pharmaceutical products manufactured or sold in Israel. Prior to joining the company, Mr. Dichter served in the Medical Corps of the Israel Defense Forces, was employed by Kupat Holim Clalit and worked in a private pharmacy. |
| Bacalu, Mariana | Mariana Bacalu joined Taro Pharmaceutical Industries in 1984 as Senior Analyst in the Quality Control Laboratory. As Vice President, Quality Affairs, she is currently responsible for quality affairs at the Haifa Bay facility. Prior to joining the company, Ms. Bacalu served as a production manager for Polymer Industry in Romania. |
| Tal, Tzvi | Tzvi Tal joined Taro Pharmaceutical Industries in 1996 and currently serves as Vice President, Information Technology, Israel. He is responsible for all information technology programs at the facilities in Israel. From 1977 to 1996, Mr. Tal was Head of Information Technology for the Vargus Group and Plant Manager for Egmo Industries. |
| Zajicek, Ram | Ram Zajicek joined Taro Pharmaceutical Industries in April of 2006 as Group Vice President, Haifa Site Manager. From 2002 to 2006, he was a partner of Tefen USA, Ltd., an international operations consulting firm. From 1998 to 2001, Mr. Zajicek was President and CEO of ProActivity Inc. |
| Reingold, Hagai | Hagai Reingold joined Taro Pharmaceutical Industries in 2002 and currently serves as Vice President, API Division in Israel. He is responsible for all API production, technology, quality and safety. From 2002 to 2004, Mr. Reingold was Supply Chain and Industrial Engineering Manager. From 2000 to 2002, Mr. Reingold worked as Industrial and Product Engineering Manager for Kulicke & Soffa Company. |
| Rothman, Inbal | Inbal Rothman joined Taro Pharmaceutical Industries in 2004 and is currently serving as Vice President, Human Resources and Community Affairs in Israel. Prior to joining the company, Ms. Rothman was an independent consultant for two years, specializing in organizational development. From 1998 to 2002, Ms. Rothman was Human Resources Director for Dexxon Ltd. |
| Shamir, Noam | Noam Shamir joined Taro Pharmaceutical Industries in 2003 and is currently serving as Vice President Supply Chain & Industrial Engineering. Prior to joining the company, Mr. Shamir was employed at Cyoptics Inc. as Chief Information Officer. From 1991 to 1997, he was Factory Manager and the Manager of Production Planning and Control at Delta Galail Industry. |
| Roof, Rebecca | Rebecca Roof joined Taro Pharmaceutical Industries in 2006 as Interim Chief Administrative and Restructuring Officer. She is a Managing Director of AlixPartners, LLC, specializing in corporate restructuring. |
| Levitt, Tal | Tal Levitt, Esq. was elected to the board of directors of Taro Pharmaceutical Industries in 1998 and is currently Secretary. Ms. Levitt joined the company in 1995 as Associate Counsel and currently serves as Senior Vice President, Corporate Affairs and Treasurer of Taro U.S.A. She previously worked as a corporate attorney at the New York law firm of Parker Chapin Flattau & Klimpl, LLP from 1994 to 1995. |
| Rafalowicz, Zahava | Zahava Rafalowicz joined Taro Pharmaceutical Industries in 1997 as Marketing Manager of Israeli operations. Ms. Rafalowicz presently serves as Group Vice President, Sales and Marketing, and Deputy General Manager in Israel. She is responsible for Israeli and European sales and marketing operations and planning. Prior to joining the company, Ms. Rafalowicz was the Deputy Managing Director of the Pharmaceutical Division of Teva Pharmaceutical Industries Ltd. She also spent several years at IMS Health Global Services, or IMS, where she established IMS in the Eastern European Bloc. |
| Rubinstein, Samuel | Samuel Rubinstein joined Taro Pharmaceutical Industries in 1990 and currently serves as Senior Vice President and General Manager. From 1986 to 1989, Mr. Rubinstein served as President of Laminated Plastics, Inc., a joint venture of two Israeli corporations operating in the United States. From 1974 until 1986, Mr. Rubinstein managed several different Israeli companies. |
| Moros, Daniel | Daniel Moros, M.D. was elected to the board of directors of Taro Pharmaceutical Industries in 1988 and is currently Vice Chairman. He is instrumental in overseeing the clinical research program, including the design and conduct of clinical trials. Dr. Moros has been Associate Professor of Neurology at the Mount Sinai School of Medicine of the City University of New York since 1991, and currently is Associate Clinical Professor at such institution. |
| Douglas, Heather | Heather Douglas, Esq. was elected to the board of directors of Taro Pharmaceutical Industries in 1998. Ms. Douglas is a partner with the Canadian law firm of Borden Ladner Gervais LLP. Ms. Douglas specializes in government finance and is responsible for the firm’s public-private partnerships initiative in Eastern Canada. |
| Johnston, Eric | Eric Johnston, Esq. was elected to the board of directors of Taro Pharmaceutical Industries in 1984. Mr. Johnston is currently an attorney in Ottawa and consultant to the Canadian law firm of Perley-Robertson, Hill and McDougall LLP. From 1974 to 1998, Mr. Johnston served as a Deputy Regional Solicitor of The Regional Municipality of Ottawa-Carleton, Ontario, Canada and from 1998 to 2001 as Regional Solicitor and Counsel. |
| Keren, Gad | Gad Keren, M.D. served on the board of directors of Taro Pharmaceutical Industries from 1991 to 2000 and was reelected in 2001. Dr. Keren is currently Chairman of the Cardiology Department at the Tel Aviv Medical Center, where he was named Professor of Cardiology in 1995, and he has been secretary of the Israel Cardiology Society since 1991. Dr. Keren was a research fellow at the National Institute of Health in 1989 and 1990. Dr. Keren also acts as a consultant to the Taro Research Institute Ltd. |
| Strober, Myron | Myron Strober, C.P.A. was elected to the board of directors of Taro Pharmaceutical Industries in 2002 and serves as the chairman of Audit Committee. A Certified Public Accountant in the United States, Mr. Strober was an audit partner of Ernst & Young, New York, from 1969 to 1990. Since his retirement in 1990, Mr. Strober has been actively involved as a financial consultant to a number of organizations. He was a financial consultant to the company from 1993 to 2002 and served on the advisory board. |
| Friedman, Micha | Micha Friedman Ph.D. was elected to the board of directors of Taro Pharmaceutical Industries in 2002 and is currently a Professor in the Department of Pharmacy at the Hebrew University of Jerusalem in Israel. He has served as Dean of the School of Pharmacy of the Hebrew University and has published numerous articles both in Israel and internationally. He is also a member of many professional pharmaceutical societies. |
| Hod, Ben | Ben Zion Hod, C.P.A. was elected to the board of directors of Taro Pharmaceutical Industries in 2003, and re-elected in 2006, as a statutory independent director. Mr. Hod is a certified public accountant in Israel and for the past 11 years, has served as company comptroller for Zim Integrated Shipping Services Ltd. Prior to joining Zim, Mr. Hod was a senior manager at Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd. Mr. Hod previously served as a public director of the Company from 1993 to 1998. |
| Fainaro, Haim | Haim Fainaro, C.P.A. was elected to the board of directors of Taro Pharmaceutical Industries in 2003, and re-elected in 2006 as a statutory independent director. He is a certified public accountant in Israel, managing a private accounting practice in Tel Aviv since 1969. Mr. Fainaro has previously served as the Company’s internal auditor in Israel and as public director from 1988 to 1993. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Levitt, Barrie | -- |
| Kolker, Ron | -- |
| Yacobi, Avraham | -- |
| Bayer, Hannah | -- |
| Kaplan, Roman | -- |
| Dichter, Yohanan | -- |
| Bacalu, Mariana | -- |
| Tal, Tzvi | -- |
| Zajicek, Ram | -- |
| Reingold, Hagai | -- |
| Rothman, Inbal | -- |
| Shamir, Noam | -- |
| Roof, Rebecca | -- |
| Levitt, Tal | -- |
| Rafalowicz, Zahava | -- |
| Rubinstein, Samuel | -- |
| Moros, Daniel | -- |
| Douglas, Heather | -- |
| Johnston, Eric | -- |
| Keren, Gad | -- |
| Strober, Myron | -- |
| Friedman, Micha | -- |
| Hod, Ben | -- |
| Fainaro, Haim | -- |
As Of
Options Compensation
| Name | Options | Value |
|---|---|---|
| Levitt, Barrie | 0 | 0 |
| Kolker, Ron | 0 | 0 |
| Yacobi, Avraham | 0 | 0 |
| Bayer, Hannah | 0 | 0 |
| Kaplan, Roman | 0 | 0 |
| Dichter, Yohanan | 0 | 0 |
| Bacalu, Mariana | 0 | 0 |
| Tal, Tzvi | 0 | 0 |
| Zajicek, Ram | 0 | 0 |
| Reingold, Hagai | 0 | 0 |
| Rothman, Inbal | 0 | 0 |
| Shamir, Noam | 0 | 0 |
| Roof, Rebecca | 0 | 0 |
| Levitt, Tal | 0 | 0 |
| Rafalowicz, Zahava | 0 | 0 |
| Rubinstein, Samuel | 0 | 0 |
| Moros, Daniel | 0 | 0 |
| Douglas, Heather | 0 | 0 |
| Johnston, Eric | 0 | 0 |
| Keren, Gad | 0 | 0 |
| Strober, Myron | 0 | 0 |
| Friedman, Micha | 0 | 0 |
| Hod, Ben | 0 | 0 |
| Fainaro, Haim | 0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
| FRANKLIN RESOURCES INC | 650,000 | $8.50 |
| FRANKLIN RESOURCES INC | 12,937 | $9.50 |
| FRANKLIN RESOURCES INC | 10,460 | $9.50 |
| FRANKLIN RESOURCES INC | 3,538 | $9.50 |
| FRANKLIN RESOURCES INC | 7,843 | $9.50 |
| FRANKLIN RESOURCES INC | 3,720 | $9.48 |
| FRANKLIN RESOURCES INC | 13,277 | $9.36 |
| FRANKLIN RESOURCES INC | 18,690 | $9.18 |
| FRANKLIN RESOURCES INC | 10,235 | $9.07 |
| FRANKLIN RESOURCES INC | 2,900 | $8.74 |
| FRANKLIN RESOURCES INC | 11,683 | $8.49 |
| FRANKLIN RESOURCES INC | 33,130 | $8.00 |
| FRANKLIN RESOURCES INC | 13,620 | $8.06 |
| FRANKLIN RESOURCES INC | 820 | $9.25 |
| FRANKLIN RESOURCES INC | 60,613 | $9.75 |
| FRANKLIN RESOURCES INC | 100 | $9.75 |
| FRANKLIN RESOURCES INC | 8,960 | $9.75 |
| FRANKLIN RESOURCES INC | 54,100 | $9.75 |
| FRANKLIN RESOURCES INC | 33,866 | $9.75 |
| FRANKLIN RESOURCES INC | 48,000 | $9.75 |
| FRANKLIN RESOURCES INC | 5,080 | $9.75 |
| FRANKLIN RESOURCES INC | 7,308 | $9.75 |
| FRANKLIN RESOURCES INC | 15,033 | $9.75 |
| FRANKLIN RESOURCES INC | 300 | $9.75 |
| FRANKLIN RESOURCES INC | 7,720 | $9.75 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
